Evommune IPO Pricing Announced
Slice of Healthcare Team
11/07/2025
Key highlights
- 9,375,000 shares priced at $16.00 each
- Expected to raise $150 million in gross proceeds
- Trading begins on NYSE under EVMN
- Underwriters include Morgan Stanley and Leerink Partners
- Closing expected on November 7, 2025
Source: PR Newswire
No quotes were given.
Why this matters
Evommune's IPO marks a significant step in the biotechnology sector, providing essential funding for innovative therapies targeting chronic inflammatory diseases, which could transform patient care. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
